Dan Ngoc Huynh1, Alyssa Millan2, Earl Quijada3, Deborah John4, Shariq Khan5, Tadashi Funahashi6. 1. Regional Assistant Medical Director, Hospital Quality, Regional Chief, Hospital Medicine, Regional Physician Director, Home Care Services, Southern California Permanente Medical Group. 2. Senior Manager, Health Innovation Studio, Southern California Permanente Medical Group. 3. Physician, Geriatric, Palliative, Continuing Care, Southern California Permanente Medical Group. 4. Consultant, Health Innovation Studio, Southern California Permanente Medical Group. 5. Principle Data Consultant, Health Innovation Studio, Southern California Permanente Medical Group. 6. Chief Innovation Officer, Health Innovation Studio, Southern California Permanente Medical Group.
Abstract
INTRODUCTION: The Southern California region of Kaiser Permanente developed a COVID-19 Home Monitoring program as an alternative to hospital admission to decrease hospital bed days and mitigate the adverse effects of a surge. To date, more than 15,000 patients have been enrolled and approximately 10% of enrolled patients have been escalated to hospital care for timely treatment. Our objective is to describe our COVID-19 Home Monitoring program and present early results. METHODS: We conducted an observational retrospective study of all patients enrolled in the COVID-19 Home Monitoring program between April 13, 2020 through February 12, 2021. Data analysis conducted includes patient demographics, enrollment, entry points, length of stay, mortality, additional treatment, utilization, adherence, satisfaction, and alert triggers. RESULTS: A total of 12,461 of 13,055 patients (95.5%) recovered and completed the program, 1387 patients (10.6%) were admitted to the hospital, and 20 patients (0.2%) died while they were being monitored at home. The mortality rate at 30 days from enrollment was 1.6%. Hospital length of stay for ambulatory patients receiving oxygen only was 5.4 days compared to 3.1 days for those ambulatory patients receiving oxygen, dexamethasone, and remdesivir. CONCLUSION: COVID-19 home monitoring appears to be safe and effective. Initial data suggest it can serve as an alternative to hospitalization, decreasing hospital length of stay when patients receive therapies in the ambulatory setting otherwise reserved for the hospital. Initial results of this Home Monitoring program appear to be promising, and a longer term prospective study is warranted.
INTRODUCTION: The Southern California region of Kaiser Permanente developed a COVID-19 Home Monitoring program as an alternative to hospital admission to decrease hospital bed days and mitigate the adverse effects of a surge. To date, more than 15,000 patients have been enrolled and approximately 10% of enrolled patients have been escalated to hospital care for timely treatment. Our objective is to describe our COVID-19 Home Monitoring program and present early results. METHODS: We conducted an observational retrospective study of all patients enrolled in the COVID-19 Home Monitoring program between April 13, 2020 through February 12, 2021. Data analysis conducted includes patient demographics, enrollment, entry points, length of stay, mortality, additional treatment, utilization, adherence, satisfaction, and alert triggers. RESULTS: A total of 12,461 of 13,055 patients (95.5%) recovered and completed the program, 1387 patients (10.6%) were admitted to the hospital, and 20 patients (0.2%) died while they were being monitored at home. The mortality rate at 30 days from enrollment was 1.6%. Hospital length of stay for ambulatory patients receiving oxygen only was 5.4 days compared to 3.1 days for those ambulatory patients receiving oxygen, dexamethasone, and remdesivir. CONCLUSION: COVID-19 home monitoring appears to be safe and effective. Initial data suggest it can serve as an alternative to hospitalization, decreasing hospital length of stay when patients receive therapies in the ambulatory setting otherwise reserved for the hospital. Initial results of this Home Monitoring program appear to be promising, and a longer term prospective study is warranted.
Authors: James G Shaw; Sandeep Sankineni; Charles A Olaleye; Kari L Johnson; Jessica L Locke; John Patino; Farzaneh L Sabi; Richard J McCarthy Journal: Telemed J E Health Date: 2021-02-05 Impact factor: 3.536
Authors: Adam L Sharp; Brian Z Huang; Benjamin Broder; Matthew Smith; George Yuen; Christopher Subject; Claudia Nau; Beth Creekmur; Sara Tartof; Michael K Gould Journal: Am J Emerg Med Date: 2020-11-05 Impact factor: 2.469
Authors: Jean Y Ko; Melissa L Danielson; Machell Town; Gordana Derado; Kurt J Greenlund; Pam Daily Kirley; Nisha B Alden; Kimberly Yousey-Hindes; Evan J Anderson; Patricia A Ryan; Sue Kim; Ruth Lynfield; Salina M Torres; Grant R Barney; Nancy M Bennett; Melissa Sutton; H Keipp Talbot; Mary Hill; Aron J Hall; Alicia M Fry; Shikha Garg; Lindsay Kim Journal: Clin Infect Dis Date: 2021-06-01 Impact factor: 9.079
Authors: Tucker Annis; Susan Pleasants; Gretchen Hultman; Elizabeth Lindemann; Joshua A Thompson; Stephanie Billecke; Sameer Badlani; Genevieve B Melton Journal: J Am Med Inform Assoc Date: 2020-08-01 Impact factor: 4.497